肿瘤免疫的血管调节。
Vascular regulation of antitumor immunity.
机构信息
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
出版信息
Science. 2019 Aug 9;365(6453):544-545. doi: 10.1126/science.aaw7875.
Abstract
Blood and lymphatic vessels regulate antitumor immunity through direct and indirect mechanisms, providing new opportunities for improving cancer immunotherapy.
摘要
血液和淋巴管通过直接和间接的机制调节抗肿瘤免疫，为改善癌症免疫治疗提供了新的机会。
相似文献
1
Vascular regulation of antitumor immunity.肿瘤免疫的血管调节。
Science. 2019 Aug 9;365(6453):544-545. doi: 10.1126/science.aaw7875.
2
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.嵌合抗原受体 T 细胞直击肿瘤微环境：克服肿瘤逃逸的策略。
Front Immunol. 2020 Jun 17;11:1109. doi: 10.3389/fimmu.2020.01109. eCollection 2020.
3
Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.肿瘤缺氧调控免疫逃逸/浸润：对血管生成的影响及缺氧生物标志物对癌症治疗的潜在影响。
Front Immunol. 2021 Jan 20;11:613114. doi: 10.3389/fimmu.2020.613114. eCollection 2020.
4
Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance.CAR-T 疗法：通往特定调节性 T 细胞耐受的曲折道路。
Front Immunol. 2021 Sep 6;12:742719. doi: 10.3389/fimmu.2021.742719. eCollection 2021.
5
Cancer therapy returns to original target: HIV.癌症治疗回归最初目标：艾滋病病毒。
Science. 2019 Aug 9;365(6453):530. doi: 10.1126/science.365.6453.530.
6
T-regulatory cells: key players in tumor immune escape and angiogenesis.调节性 T 细胞：肿瘤免疫逃逸和血管生成的关键参与者。
Cancer Res. 2012 May 1;72(9):2162-71. doi: 10.1158/0008-5472.CAN-11-3687.
7
CAR-T cells: the long and winding road to solid tumors.嵌合抗原受体 T 细胞：漫漫实体瘤征途。
Cell Death Dis. 2018 Feb 15;9(3):282. doi: 10.1038/s41419-018-0278-6.
8
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.嵌合抗原受体（CAR）T细胞在过继性癌症免疫治疗中的长期持续存在：挑战与未来方向
Front Immunol. 2020 Apr 22;11:702. doi: 10.3389/fimmu.2020.00702. eCollection 2020.
9
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.通过 CAR T 细胞过继转移来操纵肿瘤微环境。
Mamm Genome. 2018 Dec;29(11-12):739-756. doi: 10.1007/s00335-018-9756-5. Epub 2018 Jul 9.
10
Improving immune-vascular crosstalk for cancer immunotherapy.改善免疫-血管串扰以用于癌症免疫治疗。
Nat Rev Immunol. 2018 Mar;18(3):195-203. doi: 10.1038/nri.2017.145. Epub 2018 Jan 15.
引用本文的文献
1
Physiologically-based pharmacokinetic model for CAR-T cells delivery and efficacy in solid tumors.基于生理的药代动力学模型用于实体瘤中CAR-T细胞的递送与疗效研究
bioRxiv. 2025 Aug 21:2025.08.20.671229. doi: 10.1101/2025.08.20.671229.
2
Immunometabolic Targets in CD8 T Cells within the Tumor Microenvironment of Hepatocellular Carcinoma.肝细胞癌肿瘤微环境中CD8 T细胞的免疫代谢靶点
Liver Cancer. 2024 Nov 21;14(4):474-496. doi: 10.1159/000542578. eCollection 2025 Aug.
3
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.通过纳米颗粒介导的STING激动剂协同作用增强放疗诱导的抗肿瘤免疫力。
Mol Cancer. 2025 Jun 11;24(1):176. doi: 10.1186/s12943-025-02366-y.
4
Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity.阿昔替尼与程序性死亡受体配体1（PD-L1）小干扰RNA（siRNA）共递送，以实现血管正常化与免疫检查点抑制的协同作用，增强抗癌免疫力。
J Nanobiotechnology. 2025 Mar 10;23(1):194. doi: 10.1186/s12951-025-03170-y.
5
Intratumoral antigen-presenting cell activation by a nanovesicle for the concurrent tertiary lymphoid structure de novo neogenesis.纳米囊泡激活肿瘤内抗原呈递细胞以同时实现三级淋巴结构的从头新生。
Sci Adv. 2025 Feb 21;11(8):eadr1299. doi: 10.1126/sciadv.adr1299. Epub 2025 Feb 19.
6
Expression and prognostic significance of CD93 in blood vessels in colorectal cancer: an immunohistochemical analysis of 134 cases.CD93在结直肠癌血管中的表达及预后意义：134例免疫组织化学分析
BMC Gastroenterol. 2025 Feb 17;25(1):84. doi: 10.1186/s12876-025-03643-2.
7
Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.基线肿瘤血管灌注作为非小细胞肺癌免疫检查点治疗的一种非侵入性预测生物标志物。
BMJ Oncol. 2024 Aug 21;3(1):e000473. doi: 10.1136/bmjonc-2024-000473. eCollection 2024.
8
Self-Assembly Nanomedicine Initiating Cancer-Immunity Cycle with Cascade Reactions for Boosted Immunotherapy.通过级联反应启动癌症免疫循环的自组装纳米药物用于增强免疫治疗
Chem Eng J. 2025 Jan 1;503. doi: 10.1016/j.cej.2024.158143. Epub 2024 Nov 30.
9
Probing the physical hallmarks of cancer.探究癌症的物理特征。
Nat Methods. 2025 Jan 15. doi: 10.1038/s41592-024-02564-4.
10
Hybrid model of tumor growth, angiogenesis and immune response yields strategies to improve antiangiogenic therapy.肿瘤生长、血管生成和免疫反应的混合模型产生了改善抗血管生成治疗的策略。
NPJ Biol Phys Mech. 2024;1(1):4. doi: 10.1038/s44341-024-00002-2. Epub 2024 Dec 2.
本文引用的文献
1
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.肿瘤血管正常化功能：进展、机遇与挑战。
Annu Rev Physiol. 2019 Feb 10;81:505-534. doi: 10.1146/annurev-physiol-020518-114700.
2
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.肥胖在肿瘤进展和 PD-1 检查点阻断过程中对 T 细胞功能的矛盾影响。
Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.
3
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.血管灌注增加可预测免疫检查点阻断的疗效。
J Clin Invest. 2018 May 1;128(5):2104-2115. doi: 10.1172/JCI96582. Epub 2018 Apr 16.
4
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.利用抗血管生成药物增强癌症免疫治疗：机遇与挑战。
Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6.
5
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.靶向肾素-血管紧张素系统以改善癌症治疗：免疫治疗的意义。
Sci Transl Med. 2017 Oct 4;9(410). doi: 10.1126/scitranslmed.aan5616.
6
Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.耗竭调节性 T 细胞可促进肝脏内嗜肝戊型肝炎病毒新生并促进肿瘤破坏。
Cancer Immunol Res. 2017 Nov;5(11):1005-1015. doi: 10.1158/2326-6066.CIR-17-0131. Epub 2017 Sep 25.
7
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.利用淋巴管进行免疫调节：原理、机遇与挑战。
Adv Drug Deliv Rev. 2017 May 15;114:43-59. doi: 10.1016/j.addr.2017.07.005. Epub 2017 Jul 8.
8
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.双重血管生成素-2 和 VEGFA 抑制引发抗肿瘤免疫，这种免疫可被 PD-1 检查点阻断增强。
Sci Transl Med. 2017 Apr 12;9(385). doi: 10.1126/scitranslmed.aak9670.
9
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.肿瘤血管正常化与免疫刺激重编程的相互调节
Nature. 2017 Apr 13;544(7649):250-254. doi: 10.1038/nature21724. Epub 2017 Apr 3.
10
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.靶向粘着斑激酶可使胰腺癌对检查点免疫疗法产生反应。
Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.
Zotero 插件